دورية أكاديمية
Potential Anti-Tumor Activity of Kefir-Induced Juglone and Resveratrol Fractions Against Ehrlich Ascites Carcinoma-Bearing BALB/C Mice.
| العنوان: | Potential Anti-Tumor Activity of Kefir-Induced Juglone and Resveratrol Fractions Against Ehrlich Ascites Carcinoma-Bearing BALB/C Mice. |
|---|---|
| المؤلفون: | Bozkurt E; Department of Internal Medicine, Faculty of Medicine, Afyonkarahisar Health Sciences University, 03200, Afyonkarahisar, Turkey., Atay E; Department of Anatomy, Faculty of Medicine, Afyonkarahisar Health Sciences University, 03200, Afyonkarahisar, Turkey., Pektaş G; Department of Hematology, Faculty of Medicine, Mugla Sitki Kocman University, 48000, Muğla, Turkey., Ertekin A; Department of Emergency Medicine, Faculty of Medicine, Afyonkarahisar Health Sciences University, 03200, Afyonkarahisar, Turkey., Vurmaz A; Department of Medical Biochemistry, Faculty of Medicine, Afyonkarahisar Health Sciences University, 03200, Afyonkarahisar, Turkey., Korkmaz ÖA; Departmentof Chemistry, Faculty of Arts and Sciences, Yildiz Technical University, 34220, Istanbul, Turkey., Sadi G; Departmentof Biology, Faculty of Science, Karamanoglu Mehmetbey University, 70100, Karaman, Turkey., Aslan E; Department of Histology and Embryology, Faculty of Medicine, Afyonkarahisar Health Sciences University, 03200, Afyonkarahisar, Turkey., Koca OH; Department of Biochemistry, Faculty of Medicine, Karabük University, 78020, Karabük, Turkey., Pektaş MB; Department of Medical Pharmacology, Faculty of Medicine, Afyonkarahisar Health Sciences University, 03200, Afyonkarahisar, Turkey. |
| المصدر: | Iranian journal of pharmaceutical research : IJPR [Iran J Pharm Res] 2020 Summer; Vol. 19 (3), pp. 358-369. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Brieflands Country of Publication: Netherlands NLM ID: 101208407 Publication Model: Print Cited Medium: Print ISSN: 1735-0328 (Print) Linking ISSN: 17266882 NLM ISO Abbreviation: Iran J Pharm Res Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: 2022- : ['s-Hertogenbosch, The Netherlands] : Brieflands Original Publication: Tehran : School of Pharmacy, Shaheed Beheshti University of Medical Sciences and Health Services |
| مستخلص: | We investigated the potential influence of kefir-induced juglone and resveratrol fractions (JRK) against Ehrlich Ascites Carcinoma (EAC) bearing BALB/c male mice. Kefir yeast was grown in the cell culture supplemented with juglone and resveratrol (1:2). After 48 h incubation, JRK solution was applied (0.1 mL/day i.p.) to the EAC-bearing mice throughout five days. Molecular regulatory mechanisms of apoptotic and anti-apoptotic pathway components were evaluated in the plasma of mice and isolated EAC cells with ELISA, qRT-PCR, and immunocytchemical experiments. EAC-induced upregulation in Bcl-2 and downregulation in Caspase-3 were normalized with JRK in the plasma of mice. Additionally, JRK upregulated the expression levels of apoptotic Bax, p53, Caspase-3,8,9, and APAF-1 proteins together with BAX, CASPASE-8, and CASPASE-9 genes in isolated EAC cells. These changes were also associated with decreased expression levels of anti-apoptotic Bcl-2 and Bcl-xl proteins. Immunocytochemical studies also confirmed the activation of apoptotic pathways and repression of anti-apoptotic proteins in EAC cells with JRK treatment. JRK activates apoptotic pathway and inhibits anti-apoptotic genes and proteins in Ehrlich ascites carcinoma- bearing BALB/c mice that could be beneficial in cancer treatment. |
| References: | Free Radic Biol Med. 1989;6(1):63-101. (PMID: 2492250) Iran J Pharm Res. 2018 Fall;17(4):1328-1338. (PMID: 30568691) Food Funct. 2017 Dec 13;8(12):4284-4305. (PMID: 29044265) J Cell Physiol. 2019 May;234(5):6263-6273. (PMID: 30246389) Prog Biophys Mol Biol. 2015 Mar;117(2-3):250-263. (PMID: 25550083) Anticancer Agents Med Chem. 2016;16(9):1190-7. (PMID: 26845134) PLoS One. 2013;8(3):e60065. (PMID: 23533664) Oncol Lett. 2018 Aug;16(2):2579-2584. (PMID: 30013652) Oncotarget. 2017 Mar 28;8(13):20895-20908. (PMID: 28157696) Free Radic Res. 2009;43(11):1060-71. (PMID: 19707923) J Biochem Mol Toxicol. 2018 Sep;32(9):e22176. (PMID: 29992683) J Immunol. 1957 Nov;79(5):428-33. (PMID: 13491853) Life Sci. 2018 Jul 15;205:45-53. (PMID: 29705353) Oxid Med Cell Longev. 2015;2015:495305. (PMID: 25793019) J Immunol. 2009 Nov 15;183(10):6689-97. (PMID: 19846884) BMC Complement Med Ther. 2020 Apr 28;20(1):127. (PMID: 32345289) J Clin Invest. 2009 Oct;119(10):3102-14. (PMID: 19770516) Med Sci Monit. 2018 Dec 11;24:8970-8976. (PMID: 30531685) Mol Cell Biochem. 2013 Feb;374(1-2):181-90. (PMID: 23180246) Antioxidants (Basel). 2019 Apr 05;8(4):. (PMID: 30959841) Cell Physiol Biochem. 2009;23(4-6):245-54. (PMID: 19471092) Cell Death Differ. 2018 Jan;25(1):65-80. (PMID: 29149100) J Pharm Bioallied Sci. 2019 Jan-Mar;11(1):23-32. (PMID: 30906136) Can J Physiol Pharmacol. 2018 Aug;96(8):757-764. (PMID: 29527953) Eur J Pharmacol. 2010 Oct 25;645(1-3):14-22. (PMID: 20655907) Genet Mol Res. 2016 Jul 25;15(3):. (PMID: 27525860) Hypertension. 2011 Sep;58(3):431-8. (PMID: 21810655) Biochem Biophys Res Commun. 2016 Oct 7;479(1):109-15. (PMID: 27634219) J Pharmacol Sci. 2004 Feb;94(2):177-84. (PMID: 14978356) Nutr Rev. 2013 Jan;71(1):23-34. (PMID: 23282249) Cell Physiol Biochem. 2011;28(2):219-28. (PMID: 21865729) Cancer Res. 2009 Jun 1;69(11):4589-97. (PMID: 19458071) Int J Cardiol. 2005 Nov 2;105(2):209-15. (PMID: 16243115) Drug Resist Updat. 2004 Apr;7(2):97-110. (PMID: 15158766) Med Oral Patol Oral Cir Bucal. 2017 May 1;22(3):e282-e288. (PMID: 28390121) Onco Targets Ther. 2018 Dec 11;11:8995-9006. (PMID: 30588012) J Cancer Res Ther. 2019 Jan-Mar;15(1):68-74. (PMID: 30880757) Autophagy. 2012 Dec;8(12):1811-21. (PMID: 23051914) Biomed Res Int. 2016;2016:8014252. (PMID: 27066503) Int J Oncol. 2014 Mar;44(3):830-7. (PMID: 24430613) Mol Med Rep. 2017 Dec;16(6):9645-9651. (PMID: 29039537) Cureus. 2019 Feb 7;11(2):e4030. (PMID: 31011493) Food Microbiol. 2017 Sep;66:86-95. (PMID: 28576377) Eur J Pharmacol. 2011 Feb 10;652(1-3):7-14. (PMID: 21114990) Nutrients. 2017 Nov 10;9(11):. (PMID: 29125563) J Huazhong Univ Sci Technolog Med Sci. 2015 Aug;35(4):531-534. (PMID: 26223922) J Cardiovasc Pharmacol. 2006 Mar;47(3):437-45. (PMID: 16633087) Gene. 2016 Aug 15;588(1):74-8. (PMID: 27155528) PLoS One. 2007 Feb 21;2(2):e226. (PMID: 17311089) Int J Mol Med. 2018 Mar;41(3):1573-1583. (PMID: 29286102) Nanomedicine (Lond). 2019 Mar;14(5):553-573. (PMID: 30810086) J Biol Chem. 2006 Mar 10;281(10):6349-57. (PMID: 16380387) Arterioscler Thromb Vasc Biol. 2011 Feb;31(2):392-8. (PMID: 21051667) Int J Pharm. 2016 Dec 30;515(1-2):359-366. (PMID: 27744033) Biochimie. 2017 Apr;135:111-125. (PMID: 28192157) J Allergy Clin Immunol. 2007 Nov;120(5):1082-8. (PMID: 17720236) Adv Nutr. 2017 May 15;8(3):484-494. (PMID: 28507013) Sci Rep. 2018 Apr 4;8(1):5599. (PMID: 29618792) Exp Parasitol. 2015 Dec;159:100-6. (PMID: 26358271) Mol Carcinog. 2015 Jun;54(6):440-8. (PMID: 24265246) |
| فهرسة مساهمة: | Keywords: Bax; Bcl-2; Caspase; Ehrlich ascites; Juglone; Kefir; Resveratrol; p53 |
| تواريخ الأحداث: | Date Created: 20210308 Latest Revision: 20210310 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC7758008 |
| DOI: | 10.22037/ijpr.2020.112993.14060 |
| PMID: | 33680036 |
| قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!